MWNA
PHVS icon

Marshall Wace North America’s Pharvaris PHVS Stock Holding History

Marshall Wace North America’s Portfolio PHVS Stock Details PHVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-39,008
Closed -$1.09M – 1694
2021
Q1 		$1.09M Buy
+39,008
New +$1.23M ﹤0.01% 1009

Other funds holding PHVS

FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Marshall Wace North America's PHVS Position: Q2 2021 in Review

Marshall Wace North America sold out of Pharvaris (PHVS) in Q2 2021, closing a stake of 39,008 shares — an estimated $1.09M sold.

Marshall Wace North America first reported a position in PHVS in Q1 2021 and held it in 1 quarter. The position peaked at $1.09M in Q1 2021. 28 funds tracked by Wall St. Rank hold PHVS as of Q2 2021.

  • Marshall Wace North America reported no remaining Pharvaris position as of Q2 2021 after selling out during the quarter.
  • Marshall Wace North America sold 39,008 Pharvaris shares in Q2 2021, an estimated $1.09M.
  • Marshall Wace North America first reported a position in Pharvaris in Q1 2021 and held it in 1 quarter.
  • Marshall Wace North America's Pharvaris position peaked at $1.09M in Q1 2021.
  • 28 funds tracked by Wall St. Rank held Pharvaris as of Q2 2021.

Based on Marshall Wace North America's 13F filing for Q2 2021, filed 13 Aug 2021.